This article was written by June Raine in light of two recent articles published by the Pink Sheet containing comments by Dame Kate Bingham and Lord James O’Shaughnessy regarding the performance of the UK’s Medicines and Healthcare products Regulatory Agency over recent years.

Bingham contended that the MHRA has lost significant funding since Brexit, and that it requires government funding to be rebuilt.

O’Shaughnessy, meanwhile, criticized the MHRA’s past performance on clinical trials, but acknowledged that the agency had improved significantly over recent months, following a review he performed of the UK’s declining commercial clinical trial sector.

MHRA Chief On How The UK Agency Is Overhauling Its Processes To Overcome Post-Brexit Challenges

More from United Kingdom

More from Europe